Hy Stor Energy Becomes First North American Company to Commit to Global Green Hydrogen Standard
Through its partnership with the Green Hydrogen Organisation (GH2), Hy Stor Energy will also establish…
News
SetSchedule’s CEO, Roy Dekel, Nominated for the Orange County Business Journal Innovator of the Year Award 2022
SetSchedule CEO and co-founder Roy Dekel is recognized as one of the top Innovators in…
Streaming Video Technology Alliance Announces Newly Elected Board Members and Publication of New Technical Documents
Board Member Alicia Pritchett of Fastly Becomes First Woman to Take on SVTA Vice President…
Carvana Debuts New Co-Signer Financing for Texas Residents
Customers in the Lone Star State Can Now Easily Add a Co-signer When Financing with…
Silver Tree Consulting & Services Partners with Innominds to Lead IT Operations Transformation for SMBs
RALEIGH, N.C. & SAN JOSE, Calif.–(BUSINESS WIRE)–#AI—Silver Tree Consulting & Services today announced a partnership…
Code42 Incydr Restricts Insider Access and Stops Data Exfiltration of PII, Regulated and Sensitive Data with Nullafi Partnership
Joint integration redacts confidential data from files exfiltrated by high-risk and departing employees MINNEAPOLIS–(BUSINESS WIRE)–#insiderrisk—Code42…
Juniper Networks vSRX Achieves Highest Rating in Inaugural CyberRatings.org Cloud Network Firewall Test
Juniper continues to lead in independent third-party tests with excellent security and performance SUNNYVALE, Calif.–(BUSINESS…
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis SAN DIEGO, Aug….
Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies…
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or…
Albireo Appoints New Members to Board of Directors
– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President,…
The Greenrose Holding Company to Hold Second Quarter 2022 Conference Call on August 15, 2022 at 5:00 p.m. ET
AMITYVILLE, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) — The Greenrose Holding Company Inc. (OTC: GNRS,…
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and…
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
Trial to Continue as Planned SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals,…
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient…
LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients
• Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy…
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
– FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx…
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
– NULIBRY is the first and only approved therapy in the United States (U.S.) and…
TOWER ONE WIRELESS ANNOUNCES FOURTEEN TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $2,300,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF JULY 2022 VANCOUVER, BC, CANADA, Aug. 10,…